Wallace DJ, Ginzler EM, Merrill JT, et al. Sustained safety and efficacy over 10 years with belimumab (BEL) plus standard systemic lupus erythematosus (SLE) therapy (SOC) in patients with SLE. EULAR 2017, #OP0232.
MUC5B-promotervariant rs35705950 risicofactor voor RA-geassocieerde ILD
feb 2019 | ILD, Pneumonie, RA